Drugs / navoximod
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05469490 | Oct 2022 → Aug 2024 | cancer | Luke, Jason, MD | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT02471846 | Jul 2015 → Oct 2019 | cancer | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02048709 | Apr 2014 → Feb 2016 | neoplasm | Genentech, Inc. | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | navoximod | “Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors.” PMID 29921320 ↗ Jun 2018 |
| Known as | GDC-0919 | “Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors.” PMID 29921320 ↗ Jun 2018 |
| Known as | IDO-IN-7 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989951 ↗ |
| Known as | NLG-919 | “The IDO1 small molecule inhibitor navoximod (GDC-0919, NLG-919) is active as a combination therapy in multiple tumor models.” PMID 29921320 ↗ Jun 2018 |
| Known as | RG-6078 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989951 ↗ |
| Known as | RO-7077339 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989951 ↗ |
| Known as | RO7077339-001 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989951 ↗ |
| Action | Inhibit | “an investigational agent intended to inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme” NCT02048709 ↗ |
| Modality | Small molecule | “The IDO1 small molecule inhibitor navoximod (GDC-0919, NLG-919) is active as a combination therapy in multiple tumor models.” PMID 29921320 ↗ Jun 2018 |
| Route | Oral | “Starting dose of GDC-0919 will be 50 mg by mouth every 12 hour.” NCT02048709 ↗ |
| Target | IDO1 | “This is an open-label Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of GDC-0919, an investigational agent intended to...” NCT02048709 ↗ |